Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3341-3350 Newer>

The Motley Fool December 13, 2006 Matthew Crews	Less Support for Drug-Eluting Stents? The FDA responds to a recent controversy. The regulator's stance represents a good-faith-take on the newer stents, which is good news for drug companies.
The Motley Fool December 13, 2006 Stephen Albainy-Jenei	The Latest Standpoint on Stents A panel of experts reaches mixed conclusions on the safety and effectiveness of drug-coated stents. Investors, take note.
The Motley Fool December 12, 2006 Matthew Crews	Smith & Nephew, What's the Deal? A merger with Biomet would be good in many ways. But what's the right price? Investors, take note.
BusinessWeek December 18, 2006 Arlene Weintraub	Pfizer vs. the Counterfeiters Its suit against an Indian man alleging that he sold fake Viagra shows how hard it is to shut down online drug marketers.
The Motley Fool December 11, 2006 Brian Lawler	Roche's Early Present to Halozyme Assuming it works, Enhanze may be a platform technology that could be applied across a wide range of injected products. Roche isn't exactly betting the farm on its success, though, with only $20 million of guaranteed up-front money. Investors, take note.
The Motley Fool December 11, 2006 Jack Uldrich	Intuitive Surgical's Beating Heart Investors, there are a lot of reasons to like Intuitive Surgical. Better software will continue to improve surgeons' performance levels in meeting the demanding requirements of cardiovascular surgery.
The Motley Fool December 11, 2006 Brian Lawler	Weighing In on Sanofi's Acomplia With the future of Sanofi's two top drugs in the hands of the courts, plus any Acomplia approval subject to the whims of the FDA, investors should wait on the sidelines until these judicial and regulatory decisions have been made.
The Motley Fool December 11, 2006 Brian Lawler	Acorda Calls for 2 More Trials It'll be awhile before the FDA makes its decision on the pharma's new MS drug and the stock price settles down.
The Motley Fool December 8, 2006 Brian Lawler	Medarex Takes the Fast Route Medarex's lead drug gets an important yet expected designation from the FDA. Making a pharmaceutical company investment-worthy requires success in the clinic and the laboratory, but it also mandates that companies handle their finances correctly.
BusinessWeek December 18, 2006 Brian Grow et al.	Bitter Pills More and more people are buying prescription drugs from shady online marketers. That could be hazardous to their health.
<Older 3341-3350 Newer> Return to current articles.